Web Version

TargetMol Small Molecule Inhibitors and Compound Libraries

Our partner TargetMol has developed over 4,000 small molecule inhibitors and provides more than 45 different premade compound libraries to be used for:

  • Drug screening - drug design and virtual screening, target validation, model establishment, high-throughput and high-content screening, structure optimization
  • Pharmacological research - in vivo and in vitro testing of compounds to identify new uses for known drugs
  • Signaling pathways - stem cell research, epigenetics, PTK, GPCR and MAPK signaling
  • Cell research - pluripotent stem cell induction, cell inflammation, oncology

15% OFF* Compound Libraries

  • Validated biological and pharmacological activity
  • Many compounds FDA-approved
  • Structurally diverse and cell permeable
  • NMR- and HPLC-verified
  • Short delivery time
  • Detailed specifications
  • Custom compound library service

*Expires 31 December 2017.

BioCat GmbH

Im Neuenheimer Feld 584
D-69120 Heidelberg
Tel:  +49 (0) 6221 7141516
Fax: +49 (0) 6221 7141529
Email: info@biocat.com
Web: http://www.biocat.com